Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
- Conditions
- Parkinson DiseaseProgressive Supranuclear Palsy(PSP)Multiple System Atrophy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- NeuraLight
- Target Recruit Count
- 40
- Registration Number
- NCT06597071
- Locations
- 🇪🇸
Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- NeuraLight
- Target Recruit Count
- 300
- Registration Number
- NCT05862649
- Locations
- 🇺🇸
Rush University, Chicago, Illinois, United States
🇵🇹AIBILI research center, Coimbra, Portugal
🇪🇸Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients
- Conditions
- Parkinson Disease
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- NeuraLight
- Target Recruit Count
- 30
- Registration Number
- NCT05795023
- Locations
- 🇮🇱
Movement Disorders Unit, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel
Development and Validation of a Novel Eye-Tracking Software-based Platform to Extract Oculometric Measures
- Conditions
- Eye Movement
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- NeuraLight
- Target Recruit Count
- 2000
- Registration Number
- NCT05476523
- Locations
- 🇺🇸
NeuraLight, Wilmington, Delaware, United States
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients
- Conditions
- Idiopathic Parkinson Disease
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- NeuraLight
- Target Recruit Count
- 465
- Registration Number
- NCT05437003
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
- Prev
- 1
- 2
- Next
News
AI and Biomarkers Drive Precision Medicine Evolution: Industry Experts Predict $54B Gene Therapy Market by 2029
The precision medicine landscape is rapidly evolving, with gene therapies expected to generate nearly $54 billion in sales by 2029, while cell therapies are projected to reach $52 billion in the same period.